Home › Trials › NCT06382051

Improving Psoriatic Arthritis Screening for Patients with Plaque Psoriasis

A Multicenter, Prospective, Study to Evaluate the Impact of Modifying the Validated Psoriasis Epidemiology Screening Tool (PEST) on the Potential Diagnosis of Psoriatic Arthritis in Adult Patients With Moderate-to-severe Plaque Psoriasis in Canada ("ScreenX")

Not applicable Interventional Novartis · NCT06382051

This study is testing a new way to help doctors spot psoriatic arthritis earlier in patients with plaque psoriasis by adding extra questions and images to a screening tool.

Quick facts

PhaseNot applicable
Study typeInterventional
Enrollment502 (estimated)
Ages18 Years and up
SexAll
SponsorNovartis Industry-sponsored
Locations21 sites (Calgary, Alberta and 20 other locations)
Trial IDNCT06382051 on ClinicalTrials.gov

What this trial studies

This study aims to enhance the screening process for psoriatic arthritis (PsA) by adding two questions and images to the existing PEST questionnaire for patients with moderate-to-severe plaque psoriasis. Participants will complete the screening at their first dermatologist visit, and those who screen positive will undergo a comprehensive diagnostic assessment by a rheumatologist. The study will track treatment choices and status through a remote follow-up visit with the dermatologist. The goal is to improve early diagnosis and treatment pathways for patients with PsA.

Who should consider this trial

Good fit: Ideal candidates for this study are adults with moderate-to-severe plaque psoriasis who are eligible for biologic DMARDs.

Not a fit: Patients who have already been diagnosed with psoriatic arthritis or have inflammatory arthritis unrelated to PsA will not benefit from this study.

Why it matters

Potential benefit: If successful, this study could lead to earlier and more accurate diagnoses of psoriatic arthritis in patients with plaque psoriasis, improving their treatment outcomes.

How similar studies have performed: While this approach is innovative, similar studies have shown promise in improving screening methods for related conditions.

Eligibility criteria

Show full inclusion / exclusion criteria 
Key inclusion criteria:

1. Moderate-to-severe plaque PsO patients who are candidates for bDMARDs, according to physician's clinical judgement at the time of patient enrollment.
2. Adult patients at the time of informed consent signature
3. Patients able to understand and willing to comply with protocol requirements, instructions, and restrictions
4. Residents of Canada

Key exclusion criteria:

1. Patients who have previously screened positive for PsA through PEST.
2. Patients who have been diagnosed with PsA.
3. Patients who have been diagnosed with inflammatory arthritis unrelated to PsA (rheumatoid arthritis, reactive arthritis, enteropathic arthritis, axial spondyloarthritis)
4. Patients treated with a bDMARD for moderate-to-severe plaque PsO or any other medical condition within the last 6 months prior to patient enrollment.

Where this trial is running

Calgary, Alberta and 20 other locations

Study contacts

How to participate

  1. Review the eligibility criteria above with your treating physician.
  2. Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
  3. Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
View on ClinicalTrials.gov → Find more trials like this →
Conditions Plaque PsoriasisPsoriatic ArthritisPsoriasisPsAPsOImplementation SciencePsoriasis Epidemiology Screening Tool
Last reviewed 2026-06-13 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.